pharmaphorum

JUNE 8, 2021

That was the damning conclusion of the influential Institute for Clinical and Economic Review (ICER) in the US to yesterday’s approval of Aduhelm (aducanumab), the first new treatment for Alzheimer’s since 2003, which it says has “no evidentiary basis.” Patrizia Cavazzoni (@FDACDERDirector) June 7, 2021.

FDA 98

FDA Labelling 98

pharmaphorum

JUNE 2, 2022

And of course, in many cases, these drugs have higher than average price tags compared to the wider market which is due to the limited – or in most cases – non-existent competition within a treatment area.”. They added, “Existing incentives and rewards remain essential, as the economic case for investment in these areas is only marginal.”.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

NOVEMBER 16, 2022

However, R&D efforts into biological medicine have moved into the ascendency in recent times, as the treatments often offer targeted therapy and better outcomes. However, with a price tag of €1.58 However, a recently released report from the organisation could blow the price tag of Zolgensma out of the water.

130

130

pharmaphorum

JUNE 15, 2021

The adoption of New Science – a unique combination of the best in science and health technology that address significant unmet patient needs – is delivering more precise and effective treatments, but often at a higher price tag, according to new research. A new economic reality is challenging profitability .

Vaccines 90

Vaccines 90

Pharmaceutical Technology

JANUARY 27, 2023

Dr. James George, a research professor at the University of Oklahoma Health Sciences Center, said Cablivi “adds a new aspect to treatment, the prompt recovery of platelets and prompt resolution of transient neurologic symptoms”. However, Sanofi’s agreement is particularly unique in the way that it measures outcomes.

Documentation 52

Documentation Immunization Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

MARCH 17, 2023

Over the last twenty years, there has been a major rise in risk sharing agreements in the pharmaceutical space, said Alex Watt, GlobalData’s principal research analyst, at a recent webinar on the same topic. In some cases, she said, “[drug] innovation would have been otherwise hindered by their price tag alone”.

Pharmaceutical Companies 102

Pharmaceutical Companies Pharmaceutical Companies Communication 102